Influenza Vaccination Reduces Cardiovascular Risk Following Infection

Key Takeaways

• Influenza infection spikes heart attack risk sixfold in first week
• Vaccinated seniors show 50% lower excess cardiovascular risk post‑flu
• Study finds adjusted IRR 4.7 unvaccinated vs 2.4 vaccinated
• Protection strongest when vaccine given early in flu season
• Meta‑analyses confirm ~30% reduction in heart attacks from flu shots

Pulse Analysis

Influenza remains a leading cause of seasonal mortality in older adults, not only through respiratory failure but also by precipitating acute cardiovascular events. The virus triggers systemic inflammation that destabilises atherosclerotic plaques, creating a pro‑thrombotic environment that can lead to heart attacks or strokes within days of infection. As the immune system ages, its inflammatory response intensifies, amplifying these risks and contributing to the high fatality rates observed during severe flu seasons.

The Danish self‑controlled case series, covering over a decade of data, quantifies this danger: PCR‑confirmed flu cases saw a peak in first‑time hospitalisations for myocardial infarction and stroke within three days, returning to baseline after two weeks. Unvaccinated individuals experienced an adjusted incidence rate ratio (IRR) of 4.7 for cardiovascular events, while vaccinated patients’ IRR dropped to 2.4, indicating a roughly 50% risk reduction. These results echo earlier UK and Canadian studies that reported 20‑23% lower event rates and a meta‑analysis suggesting a 32% overall risk decline, reinforcing the protective role of vaccination beyond infection prevention.

For policymakers and health systems, the evidence underscores the cost‑effectiveness of expanding flu‑shot programs, especially targeting seniors before the season peaks. By averting high‑cost emergency admissions and long‑term disability from heart attacks and strokes, vaccination can generate substantial savings and improve quality of life. Clinicians should emphasise early‑season immunisation, and researchers should continue exploring the immunological mechanisms that confer cardiovascular protection, potentially guiding next‑generation vaccines designed for older populations.